Nuvation Bio Inc (NYSE: NUVB) kicked off on Monday, down -3.62% from the previous trading day, before settling in for the closing price of $9.4. Over the past 52 weeks, NUVB has traded in a range of $1.54-$9.75.
Annual sales at Healthcare sector company slipped by -49.14% over the past five years. While this was happening, its average annual earnings per share was recorded 71.52%. With a float of $239.39 million, this company’s outstanding shares have now reached $341.76 million.
Nuvation Bio Inc (NUVB) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 30.38%, while institutional ownership is 53.82%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,173,255. In this transaction CHIEF MEDICAL OFFICER of this company sold 150,000 shares at a rate of $7.82, taking the stock ownership to the 18,000 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Officer proposed sale 150,000 for $7.82, making the entire transaction worth $1,173,255.
Nuvation Bio Inc (NUVB) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.12 earnings per share (EPS), higher than consensus estimate (set at -0.12) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 71.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 55.84% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Take a look at Nuvation Bio Inc’s (NUVB) current performance indicators. Last quarter, stock had a quick ratio of 8.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 116.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Nuvation Bio Inc (NYSE: NUVB) saw its 5-day average volume 5.23 million, a negative change from its year-to-date volume of 5.62 million. As of the previous 9 days, the stock’s Stochastic %D was 74.22%.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 90.89%, which indicates a significant increase from 64.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.48 in the past 14 days, which was higher than the 0.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.68, while its 200-day Moving Average is $3.53. Nevertheless, the first resistance level for the watch stands at $9.37 in the near term. At $9.68, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.92. If the price goes on to break the first support level at $8.82, it is likely to go to the next support level at $8.58. Assuming the price breaks the second support level, the third support level stands at $8.27.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
The company with the Market Capitalisation of 3.12 billion has total of 342,833K Shares Outstanding. Its annual sales at the moment are 7,870 K in contrast with the sum of -567,940 K annual income. Company’s last quarter sales were recorded 13,120 K and last quarter income was -55,790 K.
